UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as AstraZeneca PLC (NASDAQ:AZN). AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that ...

The latest trading session saw Astrazeneca (AZN) ending at $77.47, denoting a -0.63% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.78%.

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...

Investors in AstraZeneca plc (Symbol: AZN) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AZN ...

The AstraZeneca PLC ADR AZN slid 2.30% to $74.24 Tuesday, on what proved to be an all-around dismal trading session for the ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best global stocks to buy according to hedge funds. The United States has long been a magnet ...